AIM ImmunoTech (AIM) Peer Comparison

$0.25

$0.16 (167.76%)

As on 28-Aug-2026 13:39EDT

Market cap

$8 Mln

Revenue (TTM)

$0 Mln

P/E Ratio

--

P/B Ratio

0.9

Div. Yield

0 %

Edit

	AIM ImmunoTech (AIM)	Medpace Holdings (MEDP)	Ascendis Pharma A/S - ADR	Exelixis (EXEL)	Arrowhead Pharmaceuticals (ARWR)
Market cap ($ Mln)	8	17,326	16,614	13,400	12,305
Revenue ($ Mln)	0	2,782	1,054	2,436	670
Net Profit ($ Mln)	-14.27	491.50	755.85	860.62	-319.95
Net Margin (%)	-15,021.05	17.67	71.69	35.33	-47.79
RoE (%)	--	110.09	--	42.98	-71.14
Price to Earnings	--	36.49	19.38	17.01	--
Price-To-Book	0.94	39.43	10.05	7.27	26.44

Income Statement
Liabilities
Assets
Cashflow
Ratios

Income Statement ($ Mln)

	AIM ImmunoTech (AIM)	Medpace Holdings (MEDP)	Ascendis Pharma A/S - ADR	Exelixis (EXEL)	Arrowhead Pharmaceuticals (ARWR)
Operating Revenue	0.10	2,782.29	1,054.37	2,435.92	669.50
Cost of Revenue	0.21	1,982.07	103.47	85.67	19.14
Gross Profit	-0.25	760.62	588.53	2,236.43	829.45
Operating Expenses	10.94	216.81	841.45	1,378.74	895.93
Operating Profit (EBIT)	-11.06	583.40	109.45	971.51	-226.44
Other Income	0.00	0.00	0.00	0.00	0.00
Profit before Tax	-14.27	598.92	101.11	1,035.47	-252.08
Provision for Tax	0.00	107.42	-654.74	174.84	20.05
Profit after Tax (Net Income)	-14.27	491.50	755.85	860.62	-319.95
Minority Interest	0.00	0.00	0.00	0.00	-47.83
Consolidated Profit	-7.46	0.00	0.00	0.00	0.00

Liabilities ($ Mln)

	AIM ImmunoTech (AIM)	Medpace Holdings (MEDP)	Ascendis Pharma A/S - ADR	Exelixis (EXEL)	Arrowhead Pharmaceuticals (ARWR)
Shareholder's Funds	7.74	433.86	1,435.90	1,843.76	465.53
Minority Interest	0.00	0.00	0.00	0.00	-47.83
Non-Current Liabilities	0.04	187.89	384.48	288.55	1,362.63
Current Liabilities	4.95	1,435.43	464.70	361.93	283.35
Total Liabilities	5.78	1,975.47	1,302.02	2,844.42	1,385.30

Assets ($ Mln)

	AIM ImmunoTech (AIM)	Medpace Holdings (MEDP)	Ascendis Pharma A/S - ADR	Exelixis (EXEL)	Arrowhead Pharmaceuticals (ARWR)
Non-Current Assets	2.30	1,006.90	895.24	1,243.41	440.60
Current Assets	10.43	1,050.29	1,389.84	1,250.82	1,671.41
Total Assets	5.78	1,975.47	1,302.02	2,844.42	1,385.30
Total Debt*	3.92	120.10	449.89	165.93	864.07
Net Current Assets	0.00	-385.14	0.00	888.90	1,388.07

Cashflow ($ Mln)

	AIM ImmunoTech (AIM)	Medpace Holdings (MEDP)	Ascendis Pharma A/S - ADR	Exelixis (EXEL)	Arrowhead Pharmaceuticals (ARWR)
Cash From Operating Activities	-10.96	713.22	51.77	884.27	179.55
Cash Flow from Investing Activities	1.85	-31.14	-8.15	350.44	-129.29
Cash from Financing Activities	10.39	-860.39	34.89	-969.59	74.01
Net Cash Inflow / Outflow	--	--	--	--	--

Ratios

Profitability Ratios

	AIM ImmunoTech (AIM)	Medpace Holdings (MEDP)	Ascendis Pharma A/S - ADR	Exelixis (EXEL)	Arrowhead Pharmaceuticals (ARWR)
ROCE (%)	854.22	53.56	-30.01	32.82	-0.17
ROE (%)	251.38	110.09	163.18	42.98	-71.14
ROA (%)	-75.73	15.64	26.53	29.32	-16.12
EBIT Margin (%)	-13,823.16	21.13	5.73	31.04	-0.77
Net Margin (%)	-15,021.05	17.67	71.69	35.33	-47.79
Cash Profit Margin (%)	-0.11	0.00	0.00	0.00	0.00

Growth Ratios

	AIM ImmunoTech (AIM)	Medpace Holdings (MEDP)	Ascendis Pharma A/S - ADR	Exelixis (EXEL)	Arrowhead Pharmaceuticals (ARWR)
Revenue Growth (%)	-21.49	24.67	114.85	9.23	12.22
EBIT Growth (%)	15.60	18.70	136.39	-3.99	93.17
Net Profit Growth (%)	11.73	17.50	378.76	42.89	-115.58
EPS Growth (%)	59.02	26.84	353.27	50.42	-73.87
Book Value Growth (%)	114.47	164.02	816.12	-0.70	-13.57

Valuation Ratios

	AIM ImmunoTech (AIM)	Medpace Holdings (MEDP)	Ascendis Pharma A/S - ADR	Exelixis (EXEL)	Arrowhead Pharmaceuticals (ARWR)
Price / Earnings	--	36.06	-59.76	15.79	-2,869.63
Price / Book Value	--	35.44	-80.42	5.72	10.04
Dividend Yield (%)	--	--	--	--	--
EV/EBITDA	--	28.08	-121.54	12.44	25.04
Market Cap ($ Cr)	--	--	--	--	--

Solvency Ratios

	AIM ImmunoTech (AIM)	Medpace Holdings (MEDP)	Ascendis Pharma A/S - ADR	Exelixis (EXEL)	Arrowhead Pharmaceuticals (ARWR)
Debt to Equity	0.00	0.00	0.00	0.00	1.77
Short term debt to equity ratio	0.50	0.00	0.05	0.00	0.09
Current Ratio	2.11	0.73	2.99	3.46	5.90
Quick Ratio	2.11	0.73	2.32	3.38	5.90
Interest Coverage	-11.54	--	1.62	--	-1.72

Operating Efficiency Ratios

	AIM ImmunoTech (AIM)	Medpace Holdings (MEDP)	Ascendis Pharma A/S - ADR	Exelixis (EXEL)	Arrowhead Pharmaceuticals (ARWR)
Debtors to sales (%)	0.00	15.88	21.25	13.74	1.28
Asset Turnover	0.01	0.89	0.37	0.83	0.34
Receivable days	29.05	50.42	85.52	43.48	1.50
Inventory Days	--	--	1,056.70	96.17	--
Payable days	4,329.51	6.26	331.01	147.97	221.81
Cash Conversion Cycle	--	--	811.21	-8.32	--

*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.

Annual
Quarterly